MarketCap
Facebook
X
TelegramAnnual report 2021
added 12-23-2023
Burning Rock Biotech Limited General and Administrative Expenses 2011-2026 | BNR
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Burning Rock Biotech Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 490 M | 294 M | 132 M | 88.3 M | 76 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 490 M | 76 M | 216 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Lantheus Holdings
LNTH
|
275 M | $ 74.6 | -1.49 % | $ 5.03 B |  USA |
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Bioventus
BVS
|
314 M | $ 9.28 | 3.11 % | $ 618 M | USA |
|
Biodesix
BDSX
|
80.5 M | $ 15.5 | 5.51 % | $ 2.01 B | USA |
 |
Medpace Holdings
MEDP
|
198 M | $ 465.57 | 1.89 % | $ 13.4 B | USA |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M |  Israel |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
 |
Myriad Genetics
MYGN
|
257 M | $ 4.7 | 0.86 % | $ 435 M | USA |
 |
National Research Corporation
NRC
|
54.8 M | $ 17.38 | -0.77 % | $ 389 M | USA |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | USA |
 |
Co-Diagnostics
CODX
|
14.3 M | $ 4.4 | 101.83 % | $ 129 M | USA |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M |  China |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
Pacific Biosciences of California
PACB
|
141 M | $ 1.39 | - | $ 417 M | USA |
 |
Charles River Laboratories International
CRL
|
743 M | $ 160.55 | 1.56 % | $ 7.96 B | USA |
 |
IQVIA Holdings
IQV
|
2 B | $ 168.36 | 0.81 % | $ 28.9 B | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Invitae Corporation
NVTA
|
192 M | - | - | $ 21.2 M | USA |
 |
BioNano Genomics
BNGO
|
35.2 M | $ 1.21 | -17.22 % | $ 6.59 M | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 268.55 | 2.27 % | $ 26.1 B |  Schweiz |
 |
Interpace Biosciences
IDXG
|
9.49 M | $ 1.71 | 0.73 % | $ 7.5 M | USA |
 |
Illumina
ILMN
|
1.09 B | $ 126.25 | 1.99 % | $ 20.1 B | USA |
 |
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B |  Niderland |
 |
Precipio
PRPO
|
9.45 M | $ 27.01 | 0.3 % | $ 35.1 M | USA |
 |
Personalis
PSNL
|
46.2 M | $ 7.73 | 1.58 % | $ 458 M | USA |
 |
RadNet
RDNT
|
1.82 M | $ 59.61 | -3.45 % | $ 4.48 B | USA |
 |
Celcuity
CELC
|
9.06 M | $ 101.54 | -4.89 % | $ 4.01 B | USA |
 |
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 266.82 | 0.88 % | $ 22.2 B | USA |
 |
Motus GI Holdings
MOTS
|
6.58 M | - | -34.28 % | $ 263 K | Israel |
 |
Senseonics Holdings
SENS
|
52.5 M | $ 6.74 | 1.81 % | $ 281 M | USA |
 |
Sotera Health Company
SHC
|
253 M | $ 13.89 | 0.07 % | $ 3.94 B | USA |
 |
ENDRA Life Sciences
NDRA
|
7.06 M | $ 3.49 | 0.29 % | $ 1.87 M | USA |
 |
NeoGenomics
NEO
|
273 M | $ 7.94 | -1.98 % | $ 1.02 B | USA |
 |
Soleno Therapeutics
SLNO
|
132 M | $ 30.98 | -2.33 % | $ 1.57 B | USA |
 |
Natera
NTRA
|
589 M | $ 197.02 | -1.53 % | $ 19.4 B | USA |
 |
CareDx, Inc
CDNA
|
108 M | $ 17.95 | 2.22 % | $ 957 M | USA |
 |
Neuronetics
STIM
|
31.5 M | $ 1.49 | -6.88 % | $ 98.3 M | USA |
 |
OPKO Health
OPK
|
304 M | $ 1.14 | -1.3 % | $ 791 M | USA |
 |
Castle Biosciences
CSTL
|
200 M | $ 25.59 | -0.62 % | $ 711 M | USA |
 |
DarioHealth Corp.
DRIO
|
15.2 M | $ 7.99 | 6.53 % | $ 31.8 M | Israel |
 |
DexCom
DXCM
|
1.29 B | $ 66.84 | 1.36 % | $ 26.1 B | USA |
 |
Exact Sciences Corporation
EXAS
|
889 M | $ 104.91 | - | $ 19.8 B | USA |